Global Ganja Report

Several bills now pending before the Colorado state house will further shape what the legal cannabis economy will look like in the Centennial State—for better or for worse. While some of these measures would mean a freer atmosphere both for "recreational" and medicinal users, others may portend greater big-money control of the fast-growing industry.

Amid legal challenges and disputes over zoning in Detroit, Michigan's long-awaited regulatory regime for cannabis dispensaries continues to face obstacles to implementation. This has left hundreds of dispensaries operating in a "gray market"—tolerated by the authorities on an unofficial basis while the mess is being worked out. But now state authorities have started to order these outlets closed—potentially leaving thousands of registered users without access to their medicine.

Seniors are the fastest growing group of medicinal cannabis users in the country, and a growing number of nursing homes from coast to coast are tolerating use of tinctures and extracts to combat dementia, insomnia and related ailments. Patient testimony is now backed up by research, with scientists identifying the mechanism by which cannabinoids slow the deterioration of neurons in the brain. But federal strictures continue to pose an obstacle to investigation—leaving medicinal users in the cold under US law.

Oakland-based cannabis industry research firm ArcView Group has released a new study, ambitiously entitled "The Road Map to a $57 Billion Worldwide Market." It provides a sweeping overview of recent progress and future prospects for legal or medical herb across the globe. But it also warns that, due to continued legal restrictions and bureaucratic overstretch, the market is in most areas bottlenecked from achieving its potential.

A United Nations study brings back the surprise finding that the world's biggest producer of legal cannabis is Great Britain. The answer to this seeming anomaly lies in one UK-based multinational corporation with industrial-scale grow operations for production of pharmaceuticals.

Panama may be the next Latin American country to pass a medical marijuana law, with the nation's National Assembly now debating a measure. But, in sharp contrast to that in neighboring Colombia, the Panamanian program would fly pretty close to the ground. In a play to social conservatives, the law would only allow imports, and users would be limited to extracts rather than herbaceous cannabis. And even this may face a fight from opposition lawmakers.

The process of working out implementing regulations for Peru's new medical marijuana program is now officially in extra innings, extending beyond the 60-day window that opened with the signing of the law in November. Advocates are still watching to see whether homegrown will be permitted or just lab-grown, and what constitutes a "laboratory." Meanwhile, despite this tentative progress, the cannabis-growing heartland of the Norte Chico continues to see big militarized police raids on campesino cultivation.

A judge for the US District Court for the Southern District of New York on Feb. 26 dismissed a lawsuit challenging the Schedule I classification for cannabis under the Controlled Substances Act. Judge Alvin Hellerstein granted the government's motion to dismiss because the plaintiffs failed to exhaust all administrative remedies prior to initiating the suit. The "exhaustion rule" requires "that parties exhaust prescribed administrative remedies before seeking relief from federal courts."